Article in Biomacromolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Ziqian ZhangCenter for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.
Zhangyi LuoCenter for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.ORCID 0009-0007-5791-4013
Haozhe HuangCenter for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.
Yixian HuangCenter for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.
Jieni XuCenter for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.
Xian-You LiuDepartment of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.
Wei ZhangDepartment of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.ORCID 0000-0002-9321-6411
Song LiCenter for Pharmacogenetics, Department of Pharmaceutical Science, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania 15261, United States.
Jingjing SunDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, United States.ORCID 0000-0002-6230-1015
Funding
Immunostimulatory Nanocarrier for Breast Cancer ImmunochemotherapyR01CA219399 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2017 to 2021
$2.3M
Nanoparticles-mediated combination therapy for breast cancerR01CA278608 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Song Li · 2023 to 2026
$2.0M
Combination Therapy for Pancreatic CancerR01CA270623 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Song Li · 2023 to 2026
$1.9M
Ultra-Small Epigenetic-Regulating Nanocarrier for Enhanced Synthetic Lethal TherapyR01CA287091 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jingjing Sun · 2024 to 2026
$1.8M
Nanotherapeutics for Synergistic Targeting of Myc in Prostate CancerR01CA223788 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LI, SONG · 2018 to 2022
The YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are two important transcriptional coactivators that are often aberrantly activated in cancer cells. Their dysregulation promotes cancer development and can confer resistance to anticancer therapies. Therefore, the pharmacological inhibition of YAP/TAZ presents a promising approach for treating tumors with heightened YAP/TAZ activity. However, the clinical use of a known YAP/TAZ inhibitor, niflumic acid (NA), is limited by its poor
Indexed as
Adaptor Proteins, Signal TransducingAntineoplastic AgentsBreast NeoplasmsDrug Delivery SystemsProtein Kinase InhibitorsTranscription FactorsAnimalsCell Line, TumorDasatinibFemaleHumansMiceMice, NudeNanoparticlesProdrugsTranscriptional Coactivator with PDZ-Binding Motif ProteinsAdaptor Proteins, Signal TransducingAntineoplastic AgentsDasatinibProdrugsProtein Kinase InhibitorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsYAP1 protein, humanYAP-Signaling Proteins
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
YAP/TAZ Inhibitor-Based Drug Delivery System for Selective Tumor Accumulation and Cancer Combination Therapy. · full record | Socratic